GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » Total Liabilities
中文

Praxis Precision Medicines (Praxis Precision Medicines) Total Liabilities

: $18.28 Mil (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Praxis Precision Medicines's Total Liabilities for the quarter that ended in Dec. 2023 was $18.28 Mil.

Praxis Precision Medicines's quarterly Total Liabilities declined from Jun. 2023 ($27.87 Mil) to Sep. 2023 ($19.97 Mil) and declined from Sep. 2023 ($19.97 Mil) to Dec. 2023 ($18.28 Mil).

Praxis Precision Medicines's annual Total Liabilities declined from Dec. 2021 ($41.94 Mil) to Dec. 2022 ($39.02 Mil) and declined from Dec. 2022 ($39.02 Mil) to Dec. 2023 ($18.28 Mil).


Praxis Precision Medicines Total Liabilities Historical Data

The historical data trend for Praxis Precision Medicines's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 7.58 15.72 41.94 39.02 18.28

Praxis Precision Medicines Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.02 33.92 27.87 19.97 18.28

Praxis Precision Medicines Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Praxis Precision Medicines's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.749+(1.369+-6.6613381477509E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.161+0)
=18.28

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=87.948-69.669
=18.28

Praxis Precision Medicines's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.749+(1.369+-6.6613381477509E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.161+0)
=18.28

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=87.948-69.669
=18.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Praxis Precision Medicines Total Liabilities Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Praxis Precision Medicines (Praxis Precision Medicines) Business Description

Traded in Other Exchanges
N/A
Address
99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Executives
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza officer: Chief Executive Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly officer: Chief Financial Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola officer: Principal Accounting Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Alex Nemiroff officer: General Counsel and Secretary C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154